Maternal and collateral donors were associated with a higher incidence of graft-versus-host
disease (GvHD) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) …

Introduction The novel low-dose anti-thymocyte (ATG, 5 mg/kg) plus low-dose post-
transplant cyclophosphamide (PTCy, 50 mg/kg)(low-dose ATG/PTCy)-based regimen had …

For successful transplantation using a haploidentical donor, it requires effective depletion of
T cells to reduce the risk of graft-versus-host disease (GvHD) and prevent serious GvHD …

A higher incidence of graft-versus-host disease (GVHD) has been observed after
haploidentical hematopoietic stem cell transplantation (h-HSCT) with posttransplant …

Background Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-
thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease …

Introduction Post-transplantation cyclophosphamide (PT-Cy) use is a recent graft-versus-
host disease (GVHD) prophylaxis strategy for patients undergoing allogeneic stem cell …

Haploidentical hematopoietic cell transplantation (HaploHCT) is an alternative treatment
option for patients without a suitable 10/10 HLA matched donor. We share an updated …

Antithymocyte globulin (ATG) as part of graft-versus-host disease (GVHD) prophylaxis for
peripheral blood stem cells (PBSC) transplant significantly reduced the risk of GVHD and …

The low-dose anti-thymocyte globulin (ATG) plus low-dose post transplantation
cyclophosphamide (PTCy)-based (low-dose ATG/PTCy-based) regimen had a promising …

Anti‐thymocyte globulin (ATG) or post‐transplant cyclophosphamide (PTCy)‐based
regimens are widely used for graft‐versus‐host disease (GVHD) prophylaxis in …